300239.SHE Baotou Dongbao Bio-Tech Co Ltd
- Market cap
- CNY 2.85B
- P/E
- 53.3x
- P/B
- 1.58x
- ROE
- 4.1%
- Dividend yield
- 0.64%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300239.SHE undervalued?
Graham number300239.SHE trades 93.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Baotou Dongbao Bio-Tech Co Ltd fundamental analysis
No fundamental analysis for Baotou Dongbao Bio-Tech Co Ltd yet.
Baotou Dongbao Bio-Tech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Baotou Dongbao Bio-Tech Co Ltd
Baotou Dongbao Bio-Tech Co.,Ltd engages in the design, research and development, production, and sale of gelatin and collagen in the People's Republic of China and internationally. It offers pharmaceutical gelation, food additives gelatin, and photographic gelatin; hydrolyzed collagen, collagen peptide, fish collagen peptide, and agglomerated collagen; and private label collagen and unflavored collagen jars. The company also provides organic fertilizers, water soluble fertil…
Full company profileBaotou Dongbao Bio-Tech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Baotou Dongbao Bio-Tech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 317M | 356M | 453M | 492M | 449M | 612M | 943M | 975M | 885M | 745M | 830M |
| Gross Profit | 62.8M | 72.8M | 97.4M | 90.9M | 66.9M | 96.2M | 231M | 246M | 197M | 174M | 188M |
| Operating Income | 17.9M | 26.5M | 39.2M | 36.2M | 19.8M | 41.7M | 131M | 144M | 106M | 79.9M | 91.3M |
| EBITDA | 40.9M | 53.6M | 78.6M | 72.9M | 74.3M | 102M | 225M | 232M | 195M | 163M | 89.3M |
| Net Income | 19.2M | 22.4M | 34.0M | 32.9M | 18.5M | 36.5M | 109M | 120M | 86.0M | 54.3M | 73.3M |
| EPS | 0.04 | 0.05 | 0.07 | 0.06 | 0.04 | 0.06 | 0.18 | 0.20 | 0.13 | 0.09 | 0.12 |
| Balance Sheet | |||||||||||
| Total Assets | 833M | 972M | 1.20B | 1.31B | 1.42B | 2.11B | 2.31B | 2.74B | 2.62B | 2.55B | 2.61B |
| Total Liabilities | 114M | 242M | 448M | 322M | 420M | 509M | 552M | 849M | 885M | 826M | 839M |
| Shareholders' Equity | 719M | 730M | 751M | 992M | 990M | 1.42B | 1.53B | 1.66B | 1.74B | 1.72B | 1.77B |
| Cash & Short-term Investments | 142M | 54.4M | 98.4M | 66.2M | 48.0M | 226M | 356M | 749M | 532M | 482M | 361M |
| Total Debt | 10.0M | 27.2M | 71.9M | 68.6M | 118M | 50.5M | 195M | 469M | 479M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 40.5M | -3.12M | 60.0M | -41.6M | 63.1M | 51.5M | 195M | 199M | 69.1M | 106M | - |
| Capital Expenditure | 158M | 104M | 55.2M | 129M | 152M | 51.4M | 109M | 132M | 77.2M | 79.3M | 193M |
| Free Cash Flow | -117M | -107M | 4.77M | -171M | -88.8M | 150K | 86.8M | 67.2M | -8.04M | 26.7M | -108M |
| Ratios | |||||||||||
| ROE | 2.7% | 3.1% | 4.5% | 3.3% | 1.9% | 2.6% | 7.2% | 7.2% | 4.9% | 3.2% | 4.1% |
| ROA | 2.3% | 2.3% | 2.8% | 2.5% | 1.3% | 1.7% | 4.7% | 4.4% | 3.3% | 2.1% | 2.8% |
| Net Profit Margin | 6.1% | 6.3% | 7.5% | 6.7% | 4.1% | 6.0% | 11.6% | 12.3% | 9.7% | 7.3% | 8.8% |
| Debt to Equity | 0.01x | 0.04x | 0.10x | 0.07x | 0.12x | 0.04x | 0.13x | 0.28x | 0.28x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Baotou Dongbao Bio-Tech Co Ltd dividends
- Dividend yield
- 0.64%
- Forward dividend
- 0.01 CNY
- Payout ratio
- 33.6%
- Ex-dividend date
- May 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 18.3M | 0.03 | 33.6% |
| 2024 | CNY 15.8M | 0.02 | 18.4% |
| 2023 | CNY 21.3M | 0.03 | 17.8% |
| 2022 | CNY 3.56M | 0.01 | 3.3% |
| 2021 | CNY 5.73M | 0.01 | 15.7% |
| 2020 | CNY 15.7M | 0.03 | 85.0% |
| 2019 | CNY 15.7M | 0.03 | 47.8% |
| 2018 | CNY 12.8M | 0.03 | 37.6% |
| 2017 | CNY 7.39M | 0.02 | 33.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on May 31, 2016.
Who owns Baotou Dongbao Bio-Tech Co Ltd
- Insiders 31.59%
- Institutions 5.09%
- Public & others 63.33%
- Shares outstanding 594M
- Free float 382M
Baotou Dongbao Bio-Tech Co Ltd company profile
- Company name
- Baotou Dongbao Bio-Tech Co Ltd
- Ticker
- 300239.SHE
- ISIN
- CNE100001583
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jul 6, 2011
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,424
- Fiscal year end
- December
- Address
- No. 46 Huanghe Street, Baotou, China, 014030
- Phone
- 86 47 2620 8676
- Website
- dongbaoshengwu.com
About Baotou Dongbao Bio-Tech Co Ltd
Baotou Dongbao Bio-Tech Co.,Ltd engages in the design, research and development, production, and sale of gelatin and collagen in the People's Republic of China and internationally. It offers pharmaceutical gelation, food additives gelatin, and photographic gelatin; hydrolyzed collagen, collagen peptide, fish collagen peptide, and agglomerated collagen; and private label collagen and unflavored collagen jars. The company also provides organic fertilizers, water soluble fertilizers, and compound microbial fertilizers; and industrial grade calcium hydrogen phosphate and feed grade calcium hydrogen phosphate. In addition, it is involved in the research and development, production, and sale of biological organic fertilizers, as well as empty capsules, as well as sale of terminal collagen. The company's products have applications in thickener, stabilizer, emulsifier, softgel, confection, empty hard capsules, plasma substitute, powder, tablets, beverage, and capsules, as well as fertilizers, animal feeds, industrial fields, etc. Baotou Dongbao Bio-Tech Co.,Ltd was founded in 1960 and is based in Baotou, the People's Republic of China.
Baotou Dongbao Bio-Tech Co Ltd management
8- Mr. Fang LiuGM & Director · born 1964
- Mr. Haiqing HaoChief Financial Officer · born 1976
- Mr. Furong WangDeputy GM & Director · born 1973
- Ms. Huayi ShanDeputy GM & Board Secretary · born 1983
- Mr. Gang WangDeputy General Manager · born 1976
- Mr. Jianguang DuDeputy General Manager · born 1979
- Du LiAccounting Supervisor
- Ms. Yan LiuDeputy GM & Director · born 1987